Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $1.24 billion. The enterprise value is $1.18 billion.
| Market Cap | 1.24B |
| Enterprise Value | 1.18B |
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 701.68 million shares outstanding. The number of shares has increased by 11.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 701.68M |
| Shares Change (YoY) | +11.25% |
| Shares Change (QoQ) | +50.75% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 21.01% |
| Float | 695.28M |
Valuation Ratios
The trailing PE ratio is 436.60 and the forward PE ratio is 45.43.
| PE Ratio | 436.60 |
| Forward PE | 45.43 |
| PS Ratio | 3.31 |
| Forward PS | 2.90 |
| PB Ratio | 4.49 |
| P/TBV Ratio | 8.79 |
| P/FCF Ratio | 23.07 |
| P/OCF Ratio | 22.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.81, with an EV/FCF ratio of 21.89.
| EV / Earnings | 414.27 |
| EV / Sales | 3.14 |
| EV / EBITDA | 29.81 |
| EV / EBIT | 36.06 |
| EV / FCF | 21.89 |
Financial Position
The company has a current ratio of 2.59, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.59 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 2.15 |
| Interest Coverage | 3.06 |
Financial Efficiency
Return on equity (ROE) is 1.02% and return on invested capital (ROIC) is 2.92%.
| Return on Equity (ROE) | 1.02% |
| Return on Assets (ROA) | 4.55% |
| Return on Invested Capital (ROIC) | 2.92% |
| Return on Capital Employed (ROCE) | 8.53% |
| Weighted Average Cost of Capital (WACC) | 4.66% |
| Revenue Per Employee | $924,162 |
| Profits Per Employee | $7,005 |
| Employee Count | 407 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 0.75 |
Taxes
In the past 12 months, Pharming Group has paid $10.31 million in taxes.
| Income Tax | 10.31M |
| Effective Tax Rate | 80.25% |
Stock Price Statistics
The stock price has increased by +114.34% in the last 52 weeks. The beta is 0.12, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +114.34% |
| 50-Day Moving Average | 16.24 |
| 200-Day Moving Average | 15.15 |
| Relative Strength Index (RSI) | 58.16 |
| Average Volume (20 Days) | 19,934 |
Short Selling Information
The latest short interest is 12,882, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 12,882 |
| Short Previous Month | 15,251 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.54 |
Income Statement
In the last 12 months, Pharming Group had revenue of $376.13 million and earned $2.85 million in profits. Earnings per share was $0.00.
| Revenue | 376.13M |
| Gross Profit | 330.63M |
| Operating Income | 32.76M |
| Pretax Income | 12.85M |
| Net Income | 2.85M |
| EBITDA | 39.62M |
| EBIT | 32.76M |
| Earnings Per Share (EPS) | $0.00 |
Balance Sheet
The company has $179.10 million in cash and $115.78 million in debt, with a net cash position of $63.33 million or $0.09 per share.
| Cash & Cash Equivalents | 179.10M |
| Total Debt | 115.78M |
| Net Cash | 63.33M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 277.10M |
| Book Value Per Share | 0.39 |
| Working Capital | 183.68M |
Cash Flow
In the last 12 months, operating cash flow was $54.71 million and capital expenditures -$749,000, giving a free cash flow of $53.96 million.
| Operating Cash Flow | 54.71M |
| Capital Expenditures | -749,000 |
| Depreciation & Amortization | 6.86M |
| Net Borrowing | -4.25M |
| Free Cash Flow | 53.96M |
| FCF Per Share | $0.08 |
Margins
Gross margin is 87.90%, with operating and profit margins of 8.71% and 0.76%.
| Gross Margin | 87.90% |
| Operating Margin | 8.71% |
| Pretax Margin | 3.42% |
| Profit Margin | 0.76% |
| EBITDA Margin | 10.53% |
| EBIT Margin | 8.71% |
| FCF Margin | 14.35% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.25% |
| Shareholder Yield | -11.25% |
| Earnings Yield | 0.23% |
| FCF Yield | 4.33% |
Analyst Forecast
The average price target for Pharming Group is $38.33, which is 121.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.33 |
| Price Target Difference | 121.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 12.81% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 2.84 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.84 |
| Piotroski F-Score | 5 |